Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | Director | December 20, 2017 | December 22, 2017 |
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | November 17, 2021 | November 22, 2021 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director · President & CEO | April 04, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,880 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 11,200 · Balance 23,880 F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.
HYPERION DEFI, INC.
Report date November 17, 2021 · Filed November 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 26,322 |
Reported balance
After 2021-11-17 transaction · row 1
1 source rowRow 1 · 2021-11-17 · Grant · Acquired 6,963 · Balance 26,322 F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2031-11-17 | Direct | 9,653 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Grant · Acquired 9,653 · Balance 9,653 F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Zentalis Pharmaceuticals, Inc.
Report date April 04, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,589 |
Ending reported balance
After 2022-04-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-04-04 · Sale · Disposed 10,471 · Balance 1,186,060 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. Row 2 · 2022-04-05 · Sale · Disposed 7,971 · Balance 1,178,089 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-04-05 · Sale · Disposed 2,500 · Balance 1,175,589 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 103,650 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 103,650 |
| Common StockSEC Table I · non-derivative | IndirectBy Essex Group International, LLC | 974,302 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 974,302 |
| Common StockSEC Table I · non-derivative | IndirectBy Hao Bao Zi Trust LLC | 213,600 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 213,600 F4: Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Hao Jiao Zi Trust LLC | 125,000 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 125,000 F5: Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
F5: Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2022 Filed Apr 5, 2022 22:52 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,500 | $52.11 | $130,273.00 |
DisclosureSEC source: 0001725160-22-000068 · wf-form4_164919916054278.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175,589 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2022 Filed Apr 5, 2022 22:52 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,971 | $51.34 | $409,200.85 |
DisclosureSEC source: 0001725160-22-000068 · wf-form4_164919916054278.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,178,089 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:52 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 10,471 | $48.50 | $507,843.50 |
DisclosureSEC source: 0001725160-22-000068 · wf-form4_164919916054278.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,186,060 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 22:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 700 | $50.91 | $35,639.59 |
DisclosureSEC source: 0001725160-22-000055 · wf-form4_164634545383161.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,196,531 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.55 to $51.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 22:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,771 | $50.11 | $489,625.79 |
DisclosureSEC source: 0001725160-22-000055 · wf-form4_164634545383161.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,197,231 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.54 to $50.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,700 | $50.05 | $85,086.02 |
DisclosureSEC source: 0001725160-22-000055 · wf-form4_164634545383161.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,207,002 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.98 to $50.48. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,771 | $49.74 | $436,297.61 |
DisclosureSEC source: 0001725160-22-000055 · wf-form4_164634545383161.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,208,702 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.97 to $49.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 02:08 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 525 | $50.75 | $26,642.28 |
DisclosureSEC source: 0001725160-22-000031 · wf-form4_164489087350121.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,473 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 02:08 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,208 | $50.16 | $211,090.95 |
DisclosureSEC source: 0001725160-22-000031 · wf-form4_164489087350121.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,998 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:08 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 118,319 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001725160-22-000031 · wf-form4_164489087350121.xml · derivative · entry 8 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,319 Underlying: Common Stock · 118,319 shares Expires 2032-02-09 F7 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 02:08 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 50,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000031 · wf-form4_164489087350121.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,206 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 01:03 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,343 | $58.29 | $136,578.86 |
DisclosureSEC source: 0001725160-22-000017 · wf-form4_164393660436349.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,171,775 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $58.16 to $58.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 01:03 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,128 | $57.87 | $470,386.87 |
DisclosureSEC source: 0001725160-22-000017 · wf-form4_164393660436349.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,174,118 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $57.16 to $58.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 01:03 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $59.31 | $5,931.00 |
DisclosureSEC source: 0001725160-22-000017 · wf-form4_164393660436349.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,182,246 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 01:03 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,828 | $58.59 | $165,684.60 |
DisclosureSEC source: 0001725160-22-000017 · wf-form4_164393660436349.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,182,346 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $58.24 to $59.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 01:03 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,419 | $57.63 | $197,027.74 |
DisclosureSEC source: 0001725160-22-000017 · wf-form4_164393660436349.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,185,174 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $57.21 to $58.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 01:03 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,124 | $56.81 | $234,282.79 |
DisclosureSEC source: 0001725160-22-000017 · wf-form4_164393660436349.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,188,593 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $56.21 to $57.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 44 | $80.43 | $3,538.91 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 11 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,192,717 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F11 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.35 to $80.725. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,556 | $79.54 | $123,766.73 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 10 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,192,761 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F10 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.26 to $80.13. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,871 | $78.76 | $541,140.03 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 9 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,194,317 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.24 to $79.23. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,000 | $77.71 | $155,424.60 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 8 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201,188 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.23 to $78.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 300 | $83.89 | $25,167.99 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 7 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,188 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $83.34 to $84.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 993 | $82.18 | $81,604.24 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,488 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $81.91 to $82.73. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,108 | $81.14 | $89,902.12 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,204,481 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.79 to $81.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,372 | $80.36 | $351,318.62 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,205,589 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.78 to $80.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,125 | $79.18 | $89,082.90 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,209,961 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.73 to $79.72. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,573 | $78.26 | $201,361.95 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,211,086 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.72 to $78.71. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 16, 2021 Filed Jan 5, 2022 22:49 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000006 · wf-form4_164142297445637.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,213,659 Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 124 | $78.85 | $9,777.33 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 17 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103,659 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F16 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.77 to $79.18. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,823 | $77.97 | $298,068.61 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 16 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103,783 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F15 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.74 to $78.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,824 | $77.36 | $295,811.26 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 15 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,606 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F14 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.72 to $77.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 500 | $75.99 | $37,995.00 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 14 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,430 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F13 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.62 to $76.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 600 | $74.68 | $44,809.08 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 13 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,111,930 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F12 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $74.45 to $75.29. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,289 | $73.62 | $94,900.69 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 12 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,112,530 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F11 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $73.23 to $74.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 311 | $72.76 | $22,629.79 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 11 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,819 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F10 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $72.12 to $73.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 104 | $81.12 | $8,436.48 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 10 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114,130 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,700 | $80.32 | $216,868.05 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 9 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114,234 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.11 to $80.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,502 | $79.65 | $278,946.91 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 8 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,116,934 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.10 to $80.08. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 396 | $78.59 | $31,122.99 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 7 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,436 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.07 to $79.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 500 | $77.09 | $38,546.20 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,832 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.81 to $77.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 800 | $75.85 | $60,677.04 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,121,332 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.34 to $76.20. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 921 | $74.23 | $68,369.79 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122,132 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $73.91 to $74.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,548 | $73.36 | $113,568.09 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,053 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $72.91 to $73.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 26, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Hao Jiao Zi Trust LLC Disclosed balance after: 125,000 F1 · ownership.nature: Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 26, 2021 Filed Dec 3, 2021 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000232 · wf-form4_163849059249724.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,601 Read SEC document |
| November 26, 2021 Filed Dec 8, 2021 01:35 UTC Amendment | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000236 · wf-form4a_163892732690586.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 103,650 F1 · ownership.direct: The Reporting Person's original Form 4 filed on December 2, 2021 contained an error in the form of ownership of the Common Stock gifted to the Hao Jiao Zi Trust LLC by the Reporting Person's spouse on November 26, 2021, and mistakenly indicated that these shares were gifted by the Reporting Person directly. This Form 4/A corrects the error and presents the correct number of shares of common stock beneficially owned by the Reporting Person's spouse and by the Reporting Person directly following the reported transaction. F1 · ownership.nature: The Reporting Person's original Form 4 filed on December 2, 2021 contained an error in the form of ownership of the Common Stock gifted to the Hao Jiao Zi Trust LLC by the Reporting Person's spouse on November 26, 2021, and mistakenly indicated that these shares were gifted by the Reporting Person directly. This Form 4/A corrects the error and presents the correct number of shares of common stock beneficially owned by the Reporting Person's spouse and by the Reporting Person directly following the reported transaction. Read SEC document |
| November 17, 2021 Filed Nov 22, 2021 09:16 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantStock Option (right to buy) · Derivative | 9,653 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001415889-21-005363 · form4-11222021_061140.xml · derivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,653 Underlying: Common Stock · 9,653 shares Expires 2031-11-17 F2 · derivative.exercise_date: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| November 17, 2021 Filed Nov 22, 2021 09:16 UTC | HYPERION DEFI, INC. EYEN · Entity 7220 | GrantCommon Stock, par value $.0001 | 6,963 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005363 · form4-11222021_061140.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,322 F1 · shares: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 23:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,797 | $81.10 | $307,928.35 |
DisclosureSEC source: 0001725160-21-000211 · wf-form4_163589546612485.xml · nonDerivative · entry 7 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,249,601 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.81 to $81.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 23:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,180 | $80.32 | $416,050.35 |
DisclosureSEC source: 0001725160-21-000211 · wf-form4_163589546612485.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253,398 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.81 to $80.80. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.